Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance

Clinical Microbiology Reviews

Volumn 12, Issue 4, 1999, Pages 501-517

  Ghannoum, Mahmoud A ^a,b   Rice, Louis B ^c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYLAMINE DERIVATIVE; AMPHOTECK; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN B DERIVATIVE; ECONAZOLE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; POLYENE ANTIBIOTIC AGENT; PYRROLE DERIVATIVE; TERBINAFINE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; DRUG MECHANISM; DRUG RESISTANCE; DRUG TRANSPORT; HUMAN; MYCOSIS; NONHUMAN; REVIEW; VIRULENCE;

BACTERIA (MICROORGANISMS); EUKARYOTA; PROKARYOTA;

EID: 0032882718     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/cmr.12.4.501     Document Type: Review

References (161)

1. Anaissie, E., R. Hachem, C. K-Tin-U, L. C. Stephens, and G. P. Bodey. 1993. Experimental hematogenous candidiasis caused by Candida krusei and Candida albicans: species differences in pathogenicity. Infect. Immun. 61:1268-1271.
2. Anaissie, E. J., and G. P. Bodey. 1989. Nosocomial fungal infections - old problems and new challenges. Infect. Dis. Clin. North Am. 3:867-882.
3. Arthur, M., P. Reynolds, and P. Courvalin. 1996. Glycopeptide resistance in enterococci. Trends Microbiol. 4:401-407.
4. Ather, M. A., and H. I. Winner. 1971. Development of resistance by Candida species to polyene antibiotics in vitro. J. Med. Microbiol. 4:505-517.
5. Beck-Sagué, C. M., W. R. Jarvis, and National Nosocomial Infections Surveillance System. 1993. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J. Infect. Dis. 167: 1247-1251.
6. + from Candida species. J. Antimicrob. Chemother. 11:381-383.
7. Beggs, W. H., F. A. Andrews, and G. A. Sarosi. 1981. Combined action of amphotericin B and 5-fluorocytosine on pathogenic yeasts susceptible to either drug alone. Chemotherapy 27:247-251.
8. Beggs, W. H., A. Sarosi, and M. I. Walker. 1976. Synergistic action of amphotericin B and rifampin against Candida species. J. Infect. Dis. 133: 206-209.
9. Belanger, P., C. Nast, R. Fratti, H. Sanati, and M. Ghannoum. 1997. Voriconazole (UK-109, 496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. 41:1840-1842.
10. Billot-Klein, D., L. Gutmann, D. Bryant, D. Bell, J. van Heijenoort, J. Grewal, and D. M. Shlaes. 1996. Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing levels of resistance to glycopeptide antibiotics. J. Bacteriol. 178:4696-4703.
11. Bolard, J., and J. Milhaud. 1996. Interaction of the anti-Candida amphotericin B (and other polyene antibiotics) with lipids, p. 253-274. In R. Prasad and M. Ghannoum (ed.). Lipids of pathogenic fungi. CRC Press, Inc., Boca Raton, Fla.
12. Bozzola, J. J., R. Mehta, L. Nisbet, and J. Valenta. 1984. The effect of aculeacin A and papulacandin B on morphology and cell wall ultrastructure in Candida albicans. Can. J. Microbiol. 30:857-863.
13. Capek, A., and A. Simek. 1971. Antimicrobial agents. XII. Relationship between biochemical resistance and microbial degradation of antimycotics. Folia Microbiol. 16:472-475.
14. Capek, A., A. Simek, L. Bruna, A. Svab, and Z. Budesinsk. 1974. Antimicrobial agents. XXI. Dependence of antifungal activity on the structure of the side chain in the pyrimidine group. Folia Microbiol. 19:169-171.
15. Cassone, A., R. Mason, and D. Kerridge. 1981. Lysis of growing yeast-form cells of Candida albicans by echinocandin: a cytological study. Sabouraudia 19:97-110.
16. Cassone, A., R. E. Mason, and D. Kerridge. 1979. Lysis of growing yeast-form cells of Candida albicans following cessation of growth and their possible relationship to the development of polyene resistance. J. Gen. Microbiol. 110:339-349.
17. Cheng, J. T., R. T. Witty, R. R. Robinson, and W. E. Yarger. 1982. Amphotericin B nephrotoxicity: increased renal resistance and tubule permeability. Kidney Int. 22:626-633.
18. Clark, F. S., T. Parkinson, C. A. Hitchcock, and N. A. R. Gow. 1996. Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance. Antimicrob. Agents Chemother. 40:429-425.
19. Cohen, M. L. 1992. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 257:1050-1055.
20. Cohen, S. P., H. Hachler, and S. B. Levy. 1993. Genetic and functional analysis of the multiple antibiotic resistance (mar) locus in Escherichia coli. J. Bacteriol. 175:1484-1492.
21. Defever, K., W. Whelan, A. Rogers, E. Beneke, J. Veselenak, and D. Soll. 1982. Candida albicans resistance to 5-fluorocytosine: frequency of partially resistant strains among clinical isolates. Antimicrob. Agents Chemother. 22:810-815.
22. de Kruijff, B., and R. A. Demel. 1974. Polyene antibiotic-sterol interactions in membranes of Acholeplasma laidlawaii cells and lecithin liposomes. III. Molecular structure of the polyene antibiotic-cholesterol complexes. Biochim. Biophys. Acta 339:57-70.
23. Diasio, R., J. Bennett, and C. Myers. 1978. Mode of action of 5-fluorocytosine. Biochem. Pharmacol. 27:703-707.
24. Dick, J. D., W. G. Merz, and R. Saral. 1980. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob. Agents Chemother. 18:158-163.
25. Dowson, C., T. J. Coffey, and B. G. Spratt. 1994. Origin and molecular epidemiology of penicillin-binding-protein-mediated resistance to β-lactam antibiotics. Trends Microbiol. 2:361-366.
26. Edwards, D. I. 1993. Nitroimidazole drugs - action and resistance mechanisms. II. Mechanisms of resistance. J. Antimicrob. Chemother. 31:201-210.
27. Espinel-Ingroff, A. 1997. Clinical relevance of antifungal resistance. Antimicrob. Resist. 11:929-944.
28. Fontana, R., M. Aldegheri, M. Ligozzi, H. Lopez, A. Sucari, and G. Satta. 1994. Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in Enterococcus faecium. Antimicrob. Agents Chemother. 38:1980-1983.
29. Fothergill, W. A., D. A. Sutton, and M. G. Rinaldi. 1996. An in vitro head-to-head comparison of Schering 5692, amphotericin B, fluconazole. and itraconazole against a spectrum of filamentous fungi, abstr. F89, p. 115. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemother. American Society for Microbiology, Washington, D.C.
30. Fratti, R. A., P. H. Belanger, H. Sanati, A. S. Ibrahim, and M. A. Ghannoum. 1996. The effect of the new triazole, UK-109,496 on the interactions between Candida albicans and endothelial cells in vitro, abstr. F-76, p. 155. In Abstracts of the 96th General Meeting of the American Society for Microbiology 1996. American Society for Microbiology, Washington, D.C.
31. Fryberg, M. 1974. Sterol biosynthesis in antibiotic-resistant yeast: nystatin. Arch. Biochem. Biophys. 160:83-89.
32. Gale, E. F., A. M. Johnson, D. Kerridge, and T. Y. Koh. 1975. Factors affecting the changes in amphotericin B sensitivity of Candida albicans during growth. J. Gen. Microbiol. 87:20-36.
33. Gallis, H. A., R. H. Drew, and W. W. Pickard. 1990. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:308-329.
34. Geber, A., C. A. Hitchcock, J. E. Swartz, F. S. Pullen, K. E. Marsden, K. J. Kwon-Chung, and J. Bennett. 1995. Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob. Agents Chemother. 39:2708-2717.
35. Georgopapadakou, N. H., and T. J. Walsh. 1994. Human mycoses: drugs and targets for emerging pathogens. Science 264:371-373.
36. Georgopapadakou, N. H., and T. J. Walsh. 1996. Antifungal agents: chemotherapeutic targets and immunologie strategies. Antimicrob. Agents Chemother. 40:279-291.
37. Ghannoum, M., M. Witt, A. Espinel-Ingroff, J. Ritchie, R. Larsen, and J. E. Edwards, Jr. 1994. Correlation of in vitro susceptibility testing of Cryptococcus neoformans with in vivo outcome: a comparison of two microdilution methods, abstr. F-103, p. 606. In Abstracts of the 94th General Meeting of the American Society for Microbiology 1994. American Society for Microbiology, Washington, D.C.
38. Ghannoum, M. Unpublished data
39. Ghannoum, M., I. Okagbule-Wonodi, N. Bhat, and H. Sanati. 1999. Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model. J. Chemother. 11:34-39.
40. Ghannoum, M., B. J. Spellberg, A. Ibrahim, J. A. Ritchie, B. Currie, E. Spitzer, J. E. Edwards, Jr., and A. Casadevall. 1994. Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole. Antimicrob. Agents Chemother. 38:2029-2033.
41. Gottesman, M. M., and I. Pastan. 1993. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:385-427.
42. Gottleib, D. H., H. E. Carter, J. H. Sloneker, and A. Ammann. 1958. Protection of fungi against polyene antibiotics by sterols. Science 128:361-365.
43. Graybill, J. R., E. Montalbo, W. R. Kirkpatrick, M. F. Luther, S. G. Revankar, and T. F. Patterson. 1998. Fluconazole versus Candida albicans: a complex relationship. Antimicrob. Agents Chemother. 42:2938-2942.
44. Graybill, J. R., E. Montalbo, W. R. Kirkpatrick, S. Revankar, M. Rinaldi, and T. Patterson. 1997. Candida albicans: less predictable than we may think, abstr. O49. In 13th International Conference for Human and Animal Mycology.
45. Hackbarth, C. J., T. Kocagoz, S. Kocagoz, and H. F. Chambers. 1995. Point mutations in Staphylococcus aureus PBP 2 gene affect penicillin-binding kinetics and are associated with resistance. Antimicrob. Agents Chemother. 39:103-106.
46. Hamilton-Miller, J. M. T. 1972. Physiological properties of mutagen induced variants of Candida albicans resistant to polyene antibiotics. J. Med. Microbiol. 5:425-440.
47. Hamilton-Miller, J. M. T. 1973. Chemistry and biology of the polyene macrolide antibiotics. Bacteriol. Rev. 37:166-196.
48. Hata, K., J. Ueno, H. Miki, et al. 1995. ER-30346, a novel antifungal triazole. III. In vitro activity and the mode of action, abstr. F92. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
49. Hector, R. F. 1993. Compounds active against cell walls of medically important fungi. Clin. Microbiol. Rev. 6:1-21.
50. Higgins, C. F. 1992. ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. 8:67-113.
51. Hill, E. L., G. A. Hunter, and M. N. Ellis. 1991. In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 35:2322-2328.
52. Hitchcock, C., K. Dickinson, S. B. Brown, E. G. Evans, and D. J. Adams. 1990. Interaction of azole antifungal antibiotics with cytochrome P450-dependent 14 α-sterol demethylase purified from Candida albicans. J. Biochem. 266:475-480.
53. Hitchcock, C., and P. T. Whittle. 1993. Chemistry and mode of action of fluconazole, p. 183-197. In J. W. Rippon and R. A. Fromtling (ed.), Cutaneous antifungal agents: selected compounds in clinical practice and development. Marcel Dekker, Inc., New York, N.Y.
54. Hitchcock, C. A., K. A. Barrett-Bee, and N. J. Russell. 1987. The lipid composition and permeability to azole of an azole- and polyene-resistant mutant of Candida albicans. J. Med. Vet. Mycol. 25:29-37.
55. Hitchcock, C. A., G. W. Pye, G. P. Oliver, and P. F. Troke. 1995. UK-109,496: a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity and selectivity in vitro, abstr. 2739. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
56. Holt, R. J. 1980. The imidazoles, p. 107-148. In D. C. E. Speller (ed.), Antifungal chemotherapy. John Wiley & Sons, Ltd., Chichester, England.
57. Holz, R. W. 1974. The effects of the polyene antibiotics nystatin and amphotericin B on thin lipid membranes. Ann. N. Y. Acad. Sci. 235:469-479.
58. HsuChen, C. C., and D. S. Feingold. 1973. Polyene antibiotic action on lecithin liposomes: effect of cholesterol and fatty acyl chains. Biochem. Biophys. Res. Commun. 51:972-978.
59. Itoh, K., K. Okonagi, A. Tasaka, R. Hayashi, N. Tamura, N. Tsuchimori, T. Kitazaki, Y. Matsushita, and J. Obita. 1996. TAK 187, a new antifungal triazole: Synthesis and antifungal activity, abstr. F74, p. 112. In Program and Abstracts of the 36th Interseience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
60. Iwata, K. 1992. Drug resistance in human pathogenic fungi. Eur. J. Epidemiol. 8:407-421.
61. Jenkinson, H. F. 1996. Ins and outs of antimicrobial resistance: era of the drug pumps. J. Dent. Res. 75:736-742.
62. Jessup, C. J., N. S. Ryder, and M. A. Ghannoum. 1998. Evaluation of antifungal activity of terbinafine against a broad range of pathogenic fungi, abstr. 246 Sa, p. 122. In Program and Abstracts of the 36th Annual Meeting of the Infectious Diseases Society of America.
63. Juliano, R., C. W. M. Grant, K. R. Barber, and M. A. Kalp. 1987. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol. Pharmacol. 31:1-11.
64. Jund, R., and F. Lacroute. 1970. Genetic and physiological aspects of resistance to 5-fluoropyrimidines in Saccharomyces cerevisiae. J. Bacteriol. 102:607-615.
65. Kahan, F. M., J. S. Kahan, P. J. Cassidy, and H. Kropp. 1974. The mechanism of action of fosfomycin (phosphomycin). Ann. N. Y. Acad. Sci. 235:364-386.
66. 8,7 isomerase in a Cryptococcus neoformans strain from an AIDS patients. FEMS Microbiol. Lett. 122:39-42.
67. Kerridge, D. 1980. The plasma membrane of Candida albicans and its role in the action of antifungal drugs, p. 103. In G. W. Gooday, D. Lloyd, and A. P. J. Trinci (ed.), The eukaryotic microbial cell. Cambridge University Press, Cambridge, England.
68. Kerridge, D. 1985. The protoplast membrane and antifungal drugs, p. 135. In J. F. Peberdy and L. Ferenczy (ed.), Fungal protoplasts: applications in biochemistry and genetics. Marcel Dekker Inc., New York, N.Y.
69. Kerridge, D., T. Y. Koh, M. S. Marriott, and E. F. Gale. 1976 Microbiology and plant protoplasts, p. 23-38. In J. F. Peberdy, A. H. Rose, H. J. Rodger, and E. C. Cocking (ed.), Microbiology and plant protoplasts. Churchill Livingston, London, England.
70. Kleinschmidt, M. G., K. S. Chough, and J. B. Mudd. 1972. Effect of filipin on liposomes prepared with different types of steroids. Plant Physiol. 49:852.
71. Kurtz, M. B. 1997. New antifungal drug targets: a vision for the future. ASM News 64:31-39.
72. Kurtz, M. B., and C. M. Douglas. 1997. Lipopeptide inhibitors of fungal glucan synthase. J. Med. Vet. Mycol. 35:79-86.
73. Lamb, D. C., D. E. Kelly, W. H. Schunck, A. Z. Shyadehi, M. Akhtar, D. J. Lowe, B. C. Baldwin, and S. L. Kelly. 1997. The mutation T315A in Candida albicans sterol 14 alpha-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J. Biol. Chem. 272:5682-5688.
74. Lampen, J. O., P. M. Arnow, and R. S. Safferman. 1960. Mechanism of protection by sterol against polyene antibiotics. J. Bacteriol. 80:200-206.
75. Lanyi, J., W. Z. Plachy, and M. Kates. 1974. Lipid interactions in membranes of extremely halophilic bacteria. II. Modification of the bilayer structure by squalene. Biochemistry 13:4914-4920.
76. Larsen, R. A., S. A. Bozzette, and B. E. Jones. 1994. Fluconazole combined with flucytosine for cryptococcal meningitis in persons with AIDS. Clin. Infect. Dis. 19:741-745.
77. Law, D., and D. W. Denning. 1996. In vitro activity of Schering 56592, compared with fluconazole and itraconazole against Candida spp., abstr. F88, p. 115. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
78. Leclerq, R., S. Dutka-Malen, A. Brisson-Noel, C. Molinas, E. Derlot, M. Arthur, J. Duval, and P. Courvalin. 1992. Resistance of enterococci to aminoglycosides and glycopeptides. Clin. Infect. Dis. 15:495-501.
79. Levy, S. B. 1990. Starting life resistance-free. N. Engl. J. Med. 323:335-337.
80. Li, X.-Z., D. Ma, D. M. Livermore, and H. Nikaido. 1994. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to β-lactam resistance. Antimicrob. Agents Chemother. 38:1742-1752.
81. Limaye, A. P., R. K. Gautom, D. Black, and T. R. Fritsche. 1997. Rapid emergence of resistance to cefepime during treatment. Clin. Infect. Dis. 25:339-340.
82. Livermore, D. M. 1992. Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 36:2046-2048.
83. Lopez-Berestein, G., G. Bodey, L. S. Frankel, and K. Mehta. 1987. Treatment of hepatosplenic candidiasis with liposomal amphotericin. Br. Clin. Oncol. 5:310-317.
84. Mago, N., and G. K. Khuller. 1989. Influence of lipid composition on the sensitivity of Candida albicans to antifungal agents. Indian J. Biochem. Biophys. 26:30-33.
85. Martins, M. D., and J. H. Rex. 1996. Resistance to antifungal agents in the critical care setting: problems and perspectives. New Horizons 4:338-344.
86. Mbongo, N., P. M. Loiseau, M. A. Billion, and M. Robert-Gero. 1998. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 42:352-357.
87. McGinnis, M., and M. G. Rinaldi. 1996. Antifungal drugs: mechanisms of action, drug resistance, susceptibility testing, and assays of activity in biological fluids, p. 176-211. In V. Lorian (ed.), Antibiotics in laboratory medicine. The Williams & Wilkins Co., Baltimore, Md.
88. Medoff, G., M. Comfort, and G. S. Kobayashi. 1971. Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. Proc. Soc. Exp. Biol. Med. 138:571-574.
89. Michaelis, S., and C. Berkower. 1995. Sequence comparison of yeast ATP binding cassette (ABC) proteins. Cold Spring Harbor Symp. Quant. Biol. 60:291-309.
90. Milefchik, E., M. A. Leal, R. Haubrich, R. See, S. A. Bozzette, and R. Larsen. 1993. High dose fluconazole with and without flucytosine for AIDS associated cryptococcal meningitis, abstr. WS-B5-12. In Programs and Abstracts of the 9th International Conference on AIDS/4th STD World Congress.
91. Mizoguchi, J., T. Saito, K. Mizuno, and K. Hayano. 1977. On the mode of action of a new antifungal antibiotic, aculeacin A: inhibition of cell wall synthesis of Saccharomyces cerevisiae. J. Antibiot. 30:308-313.
92. 14C-labelled streptomycin by enterococci. J. Clin. Investig. 50:2580-2584.
93. Molzahn, S. W., and R. A. Woods. 1972. Polyene resistance and the isolation of sterol mutants in Saccharomyces cerevisiae. J. Gen. Microbiol. 72: 339-348.
94. Munayyer, H., K. J. Shaw, R. S. Hare, B. Salisbury, L. Heimark, B. Pramanik, and J. R. Greene. 1996. SCH 56592 is a potent inhibitor of sterol C-14 demethylation in fungi, abstr. F92, p. 115. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
95. Nakamura, T., R. Sakai, J. Sonada, T. Katoh, T. Kaneko, and T. Horie. 1995. ER-30346, a novel antifungal triazole. IV. Pharmacokinetic and toxicological studies in mice, rats, and dogs, abstr. F94, p. 129. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
96. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
97. Neyfakh, A. A., C. M. Borsch, and G. W. Kaatz. 1993. Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrob. Agents Chemother. 37:128-129.
98. Norman, A. W., R. A. Demel, B. de Kruijff, W. S. M. Guerts-van Kessel, and L. L. M. Van Deenen. 1972. Studies on the biological properties of polyene antibiotics: comparison of other polyenes with filipin in their ability to interact specifically with sterol. Biochim. Biophys. Acta 290:1-14.
99. Norman, A. W., R. A. Demel, B. de Kruijff, and L. L. M. Van Deenen. 1972. Studies on the biological properties of polyene antibiotics. Evidence for the direct interaction of filipin with cholesterol. J. Biol. Chem. 247:1918-1929.
100. Normark, S., and J. Schonebeck. 1972. In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata. Antimicrob. Agents Chemother. 2:114-121.
101. Nozawa, Y., and T. Morita. 1986. Molecular mechanisms of antifungal agents associated with membrane ergosterol. Dysfunction of membrane ergosterol and inhibition of ergosterol biosynthesis, p. 111. In K. Iwata and H. Vanden Bossche (ed.), In vitro and in vivo evaluation of antifungal agents. Elsevier Science Publishers, B. V., Amsterdam, The Netherlands.
102. Orozco, A., L. Higginbotham, C. Hitchcock, T. Parkinson, D. Falconer, A. Ibrahim, M. Ghannoum, and S. G. Filler. 1998. Mechanism of fluconazole resistance in Candida krusei. Antimicrob. Agents Chemother. 42:2645-2649.
103. Pangon, B., C. Bizet, A. Bure, F. Pichon, A. Phillipon, B. Regnier, and L. Gutmann. 1989. In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 β-lactamase. J. Infect. Dis. 159:1005-1006.
104. Parkinson, T., D. J. Falconer, and C. Hitchcock. 1995. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrob. Agents Chemother. 39:1696-1699.
105. Parks, L. W., and W. M. Casey. 1996. Fungal sterols, p. 63-82. In R. Prasad and M. Ghannoum (ed.), Lipids of pathogenic fungi. CRC Press, Inc., Boca Raton, Fla.
106. Payne, N. I., R. F. Cosgrove, A. P. Green, and L. Liu. 1987. In vivo studies of amphotericin B liposomes derived from proliposomes; effect of formulation on toxicity and tissue disposition of the drug in mice. J. Pharm. Pharmacol. 39:24-28.
107. Perfect, J. R., and W. A. Schell. 1995. In vitro efficacy of the azole, SCH 56592, compared to amphotericin B, fluconazole, and itraconazole versus Cryptococcus neoformans, abstr. F64, p. 124. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
108. Pfaller, M., J. Riley, and T. Koerner. 1989. Effect of cilofungin (LY121019) on carbohydrate and sterol composition of Candida albicans. Eur. J. Clin. Microbiol. Infect. Dis. 8:1067-1070.
109. Polak, A., and H. Scholer. 1975. Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapia 21:113-130.
110. Polak, A., H. J. Scholer, and M. Wall. 1982. Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. Exp. Chemother. 28:461-479.
111. Poulain, D., J. F. Tronchin Dubremetz, and J. Biguet. 1978. Ultrastructure of the cell wall of Candida albicans blastospores: study of the constitutive layers by the use of a cytochemical technique revealing polysaccharides. Ann. Microbiol. 129A:141-153.
112. Prasad, R., P. De Wergifosse, A. Goffeau, and E. Balzi. 1995. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr. Genet. 27: 320-329.
113. Rao, T. V. G., S. Das, and R. Prasad. 1985. Effect of phospholipid enrichment on nystatin action: differences in antibiotic sensitivity between in vivo and in vitro conditions. Microbios 42:145-153.
114. Rao, T. V. G., A. Trivedi, and R. Prasad. 1985. Phospholipid enrichment of Saccharomyces cerevisiae and its effect on polyene sensitivity. Can. J. Microbiol. 31:322-326.
115. Redding, S. J., J. Smith, G. Farinacci, M. Rinaldi, A. Fothergill, J. Rhine-Chalberg, and M. Pfaller. 1994. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin. Infect. Dis. 18:240-242.
116. Rex, J. H., M. Rinaldi, and M. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8.
117. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1996. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
118. Roessner, C. A., C. Min, S. H. Hardin, H. L. Harris, J. C. McColum, and A. I. Scott. 1993. Sequence of the Candida albicans erg7 gene. Gene 127: 149-150.
119. Ryder, N., and B. Favre. 1997. Antifungal activity and mechanism of action of terbinafine. Rev. Contemp. Pharmacother. 8:275-287.
120. Ryder, N. S., G. Seidl, and P. Troke. 1984. Effect of the antimycotic drug naftifine on growth of and sterol biosynthesis in Candida albicans. Antimicrob. Agents Chemother. 25:483-487.
121. Samaranayake, Y. H., and L. P. Samaranayake. 1994. Candida krusei: biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen. Med. Microbiol. 41:295-310.
122. Sanati, H., P. Belanger, R. Fratti, and M. Ghannoum. 1997. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob. Agents Chemother. 41:2492-2496.
123. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1996. Susceptibility of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob. Agents Chemother. 40:2300-2305.
124. Sanglard, D., K. Kuchler, F. Ischer, J. L. Pagani, M. Monod, and J. Bille. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39:2378-2386.
125. Schulman, J. A., et al. 1988. Fatal disseminated cryptococcosis following intraocular involvement. Br. J. Ophthalmol. 72:171-175.
126. Sheehan, D. J. (Pfizer Pharmaceuticals Group). Personal communication.
127. Sheehan, D. J., C. A. Hitchcock, and C. M. Sibley. 1999. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 12:40-79.
128. Shlaes, D. M., D. N. Gerding, J. F. John, Jr., W. A. Craig, D. L. Bornstein, R. A. Duncan, et al. 1997. Society for Healthcare Epidemiology of America and Infectious Diseases Society of American Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin. Infect. Dis. 25:584-599.
129. Smith, K. J., D. W. Warnock, C. T. C. Kennedy, E. M. Johnson, V. Hopwood, J. Van Cutsem, and H. Vanden Bossche. 1986. Azole resistance in Candida albicans. J. Med. Vet. Mycology 24:133-144.
130. Sokol-Anderson, M. L., J. Brajtburg, and G. Medoff. 1986. Sensitivity of Candida albicans to amphotericin B administered as single or fractionated doses. Antimicrob. Agents Chemother. 29:701.
131. Stevens, D. A., M. J. Devine, M. Martinez, and B. Aristizabal. 1995. In vitro antifungal activity of novel azole derivatives with a morpholine ring, abstr. F85, p. 127. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
132. Stiller, R., J. Bennett, J. Scholer, M. Wall, A. Polak, and D. A. Stevens. 1982. Susceptibilitv to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob. Agents Chemother. 22:482-487.
133. Sud, I. J., and D. S. Feingold. 1981. Mechanisms of action of the antimycotic imidazoles. J. Investig. Dermatol. 76:428-441.
134. Sugar, A. M. 1986. The polyene macrolide antifungal drugs, p. 229-244. In P. K. Peterson and J. Verhoef (ed.), Antimicrobial agents, vol. 1. Elsevier Science Publishers B.V., Amsterdam, The Netherlands.
135. Sugar, A. M., and X. P. Liu. 1995. In vitro activity of SCH against Blastomyces dermatitidis (Bd), abstr. F65, p. 124. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
136. Sullivan, P. A., Y. Y. Chiew, C. Molloy, M. D. Templeton, and M. G. Shepard. 1983. An analysis of the metabolism and cell wall composition of Candida albicans during germ tube formation. Can. J. Microbiol. 29:1514-1525.
137. Surarit, R., P. K. Gopal, and M. G. Shepard. 1988. Evidence for a glycosidic linkage between chitin and glucan in the cell wall of Candida albicans. J. Gen. Microbiol. 134:1723-1730.
138. Tatsumi, Y., M. Yokoo, T. Aarika, K. Ogura, K. Nagal, and T. Naito. 1996. Therapeutic efficacy of KP-103, a novel topical antifungal triazole, on experimental superficial mycosis, abstr. F80, p. 113. In Program and Abstracts of the 36th Intersciencc Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
139. Titsworth, E., and E. Grunberg. 1973. Chemotherapeutic activity of 5-fluorocytosine and amphotericin B against Candida albicans in mice. Antimicrob. Agents Chemother. 4:306-308.
140. Tkacz, J. S. 1996. Glucan biosynthesis in fungi and its inhibition, p. 495-523. In J. Sutcliffe and N. H. Georgopapadakou (ed.), Emerging targets in antibacterial and antifungal chemotherapy. Chapman & Hall, New York, N.Y.
141. Traxler, P., J. Gruner, and J. Auden. 1977. Papulacandins, a new family of antibiotics with antifungal activity II. Isolation, chemical and biological characterization of papulacandins A, B, C, D, and E. J. Antibiot. 30:289-296.
142. Vanden Bossche, H., H. P. Marichal, L. Le Jeune, M. Coene, J. Gorrens, and W. Cools. 1993. Effects of itraconazole on cytochrome P-450-dependent 14 α-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans. Antimicrob. Agents Chemother. 37:2101-2105.
143. Vanden Bossche, H., H. P. Marichal, F. Odds, L. Le Jeune, and M.-C. Coene. 1992. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob. Agents Chemother. 36:2602-2610.
144. Vanden Bossche, H., and G. Willemsens. 1982. Effect of the antimycotics, miconazole and ketoconazole on cytochrome P450 in yeast microsomes and rat liver microsomes. Arch. Int. Physiol. Biochem. 90:B218-B219.
145. Vanden Bossche, H., G. Willemsens, W. Cools, W. F. J. Lauwers, and L. Le Jeune. 1978. Biochemical effect of miconazole on fungi. II. Inhibition of ergosterol biosynthesis in Candida albicans. Chem. Biol. Interact. 21:59-78.
146. Vanden Bossche, H., G. Willemsens, W. Cools, H. H. Marichal, and W. F. J. Lauwers. 1983. Hypothesis on the molecular basis of the antifungal activity of N-substituted imidazoles and triazoles. Biochem. Soc. Trans. 11:665-667.
147. Wallace, T. L., V. Paeznick, P. A. Cassum, and E. Anaissie. 1996. Nyotran (Liposomal nystatin) against disseminated Aspergillus fumigatus in neutropenic mice, abstr. B53, p. 31. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
148. Walsh, T. J., M. Kasai, A. Francesconi, D. Landsman, and S. J. Chanock. 1996. New evidence that Candida albicans possesses additional ATP-binding cassette MDR-like genes: implications for antifungal azole resistance. J. Med. Vet. Mycol. 35:133-137.
149. Walsh, T. J., J. W. Lee, P. Kelley, J. Bacher, J. Lecciones, V. Thomas, C. Lyman, D. Coleman, and R. S. Gordee. 1991. The antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3 β-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions of cilofungin in treatment of experimental disseminated candidiasis. Antimicrob. Agents Chemother. 35:1321-1328.
150. Wey, S. B., M. Mori, M. Pfaller, R. F. Woolson, and R. P. Wenzel. 1988. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch. Intern. Med. 148:2642-2645.
151. Whelan, W. L. 1987. The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans. Crit. Rev. Microbiol. 15:45-56.
152. Whelan, W. L., and D. Kerridge. 1984. Decreased activity of UMP pyrophosphorylase associated with resistance to 5-fluorocytosine in Candida albicans. Antimicrob. Agents Chemother. 26:570-574.
153. White, T. C. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1482-1487.
154. White, T. C. 1997. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14 α-demethylase in Candida albicans. Antimicrob. Agents Chemother. 41:1488-1494.
155. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
156. Wiebe, V. J., and M. W. DeGregorio. 1988. Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections. Rev. Infect. Dis. 10:1097-1101.
157. Witt, M., R. Larsen, E. Milefchik, M. A. Leal, R. Haubrich, J. Ritchie, J. E. Edwards, Jr., and M. Ghannoum. 1996. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole therapy: the role of antifungal testing. Clin. Infect. Dis. 22:322-328.
158. Yokoyama, K., L. Wang, and M. Miyaji. 1996. SSY726, a new triazole antifungal agent: in vitro and in vivo evaluation, abstr. F75, p. 113. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
159. Zhou, X. Y., F. Bordon, D. Sirot, M. D. Kitzis, and L. Gutmann. 1994. Emergence of clinical isolates of Escherichia coli producing THM-1 derivatives or an OXA-1 β-lactamase conferring resistance to β-lactamase inhibitors. Antimicrob. Agents Chemother. 38:1085-1089.
160. Zorzi, W., X. Y. Zhou, O. Dardenne, J. Lamotte, D. Raze, J. Pierre, L. Gutmann, and J. Coyette. 1996. Structure of the low-affinity penicillin-binding protein 5 PBP5fm in wild-type and highly penicillin-resistant strains of Enterococcus faecium. J. Bacteriol. 178:4948-4957.
161. Zygmunt, W. A., and P. A. Tavormina. 1966. Steroid interference with antifungal activity of polyene antibiotics. Appl. Microbiol. 14:865-869.